Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

60 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05562830 2026-03-16

MK-3475-04A

48 enrolled

Carcinoma, Transitional Cell

NCT06863272 2026-03-16

IDeate-Prostate02

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07232602 2026-03-16

MK-3475-04D

55 enrolled

Urinary Bladder Neoplasms

NCT07239596 2026-03-16

Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom

139 enrolled

Advanced Renal Cell Carcinoma

NCT07258407 2026-03-16

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

180 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT07287995 2026-03-16

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

BreastGenitourinaryThoracic

428 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06353386 2026-03-13

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT07468851 2026-03-13

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

180 enrolled

High-risk Non-muscle-invasive Bladder Cancer

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

300 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05417594 2026-03-12

CERTIS1

BreastCNSGastrointestinalGenitourinaryGynecologic

695 enrolled

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07259213 2026-03-12

RAD402

73 enrolled

Castration-resistant Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

102 enrolled 39 charts

Prostatic Neoplasms

NCT07181161 2026-03-06

SEACLIFF

177 enrolled

Prostatic Neoplasms

NCT05721222 2026-03-04

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

GenitourinaryHead & NeckLymphoid

42 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

NCT07293351 2026-03-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

234 enrolled

Carcinoma, Renal Cell

NCT05287945 2026-03-03

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

75 enrolled

Carcinoma, Renal Cell

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

BreastGenitourinaryLymphoidThoracic

174 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

120 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05413850 2026-03-02

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

82 enrolled

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07206056 2026-03-02

TulmiSTAR-01

188 enrolled

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT07227415 2026-03-02

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

224 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

370 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04895709 2026-02-25

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06171789 2026-02-25

PRO1107 in Patients With Advanced Solid Tumors

BreastGenitourinaryGynecologicThoracic

33 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01171898 2026-02-24

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms

NCT06267729 2026-02-23

APOLLO

60 enrolled

Prostatic Neoplasms

NCT07192614 2026-02-23

ACTIVATED-4-PC

52 enrolled

Prostatic Neoplasms

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT05720130 2026-02-20

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

100 enrolled

Prostatic Neoplasms

NCT07222488 2026-02-20

MK-3120-003

45 enrolled

Urinary Bladder Neoplasms

NCT04644068 2026-02-19

PETRA

BreastGastrointestinalGenitourinaryGynecologicThoracic

702 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05710848 2026-02-19

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

75 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07049926 2026-02-19

MK-3475-03C

140 enrolled

Carcinoma, Renal Cell

NCT07332455 2026-02-19

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

54 enrolled

Prostatic Neoplasms

NCT07421700 2026-02-19

A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

132 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05267626 2026-02-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

159 enrolled

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT06483334 2026-02-18

MK-3475-04C

38 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07145255 2026-02-17

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

BreastGastrointestinalGenitourinaryThoracic

150 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07226986 2026-02-17

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

123 enrolled

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT04626479 2026-02-12

MK-3475-03A

400 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07407283 2026-02-12

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

BreastCNSDermatologicGenitourinary

125 enrolled

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT06716853 2026-02-09

TEM-GU

10 enrolled